A new trade deal could have a big impact on Virginia’s economy.
Imagine a future free of allergic reactions, lupus and cancer. Virginia scientists are already working to make this a reality: Two Virginia Bioinformatics Institute researchers have created software that predicts allergens; Charlottesville-based AMPEL Biosolutions is pioneering a potential treatment for the chronic autoimmune disease lupus; and Manassas-based MicroVAX has just begun clinical testing on a vaccine for cancer. Virginia’s biotechnology sector is literally saving lives.
It’s also improving the day-to-day lives of thousands of commonwealth citizens in the form of high-skill, well-paying work. In 2011 the Virginia biopharmaceutical sector supported nearly $8 billion in economic output and provided more than 10,700 jobs.